These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus.
    Author: Georg-Fries B, Biederlack S, Wolf J, zur Hausen H.
    Journal: Virology; 1984 Apr 15; 134(1):64-71. PubMed ID: 6200995.
    Abstract:
    A new type of defective parvovirus, tentatively designated as adeno-associated virus type 5 (AAV-5), is characterized as far as its proteins, its helper dependence, and its seroepidemiology are concerned. The protein analysis of AAV-5 in polyacrylamide gels demonstrated the presence of three structural polypeptides, corresponding to VP 1, VP 2, and VP 3 of other AAV types. The preparation of monoclonal antibodies against AAV-5 permitted the analysis of viral structural antigen expression by using adenovirus type 12 (Ad 12) or several herpes group viruses as helper viruses, respectively. AAV-5-infected cell cultures coinfected with either Ad 12, Herpes simplex virus (HSV), Cytomegalovirus (CMV), or Varicella Zoster virus (VZV) efficiently synthesize AAV-5 specific antigens. Epstein-Barr virus (EBV) and Herpesvirus saimiri, in contrast, provide only a very weak helper activity for AAV 5 antigen expression. The development of a specific ELISA test permitted screening of human sera for antibodies to AAV-5. Forty-five percent of 926 sera from all age groups and approximately 60% of the adult population reveal antibodies to structural components of this virus. The seroepidemiology differs from that reported for other AAV serotypes. Highest average titers against AAV-5 are observed in the age group between 15 and 20 years. Sera from patients with cervical carcinoma revealed average titers of antibodies well below those of age-matched control groups. Attempts to find higher antibody levels against AAV-5 in specific human diseases failed thus far.
    [Abstract] [Full Text] [Related] [New Search]